Gary Richardson

EmailGary.Richardsonmonashedu

Accepting PhD Students

PhD projects

<a href="https://www.monash.edu/medicine/research/supervisorconnect" onclick="target='_blank';">https://www.monash.edu/medicine/research/supervisorconnect</a>

Research activity per year

2 Not started
17 Active
47 Finished

2 results

Filter

Not started

A Phase 1/2, first-in-human, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics and efficacy of a trispecific EGFR/cMET antibody GB263T in subjects with advanced non-small cell lung cancer (NSCLC) and other solid tumors [GB263T-FIH001].
Richardson, G. (Primary Chief Investigator (PCI)) & Spence, A. (Project Manager)
Project: Research
A Phase 1/2, Open-label Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects with Advanced Solid Tumours with a KRAS p.G12C Mutation [D3S-001-100].
Richardson, G. (Primary Chief Investigator (PCI)) & Spence, A. (Project Manager)
Project: Research

Gary Richardson

Projects

Search results

A Phase 1/2, first-in-human, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics and efficacy of a trispecific EGFR/cMET antibody GB263T in subjects with advanced non-small cell lung cancer (NSCLC) and other solid tumors [GB263T-FIH001].

A Phase 1/2, Open-label Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects with Advanced Solid Tumours with a KRAS p.G12C Mutation [D3S-001-100].